ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements
Windlas Biotech reported record quarterly revenue driven by 29% growth in CDMO vertical. Management focuses on operational excellence and capacity expansion via Plant 6 commercialization.
Windlas Biotech reported Q1FY27 revenue of ₹248 Cr (18% YoY). Adjusted EBITDA and PAT grew 26% and 37% respectively, excluding ESOP costs, driven by CDMO expansion.
Windlas Biotech Ltd reported revenue from operations of ₹248.1 Cr (+18.1% YoY) and net profit of ₹17.7 Cr (+0.0% YoY) for Q1 FY27.
Windlas Biotech reported record FY26 revenue of ₹904cr (up 19% YoY) and highest post-listing EPS of ₹31.60. Management emphasized scalability, capital efficiency (ROCE/ROE >25%), and diversification into injectables and exports.
Windlas Biotech reported record annual revenue of ₹904 Cr in FY26, a 19% YoY growth, driven by its CDMO vertical. The company maintained a strong net liquidity position of ₹251 Cr with zero net debt.
Windlas Biotech Ltd reported revenue from operations of ₹238.5 Cr (+17.7% YoY) and net profit of ₹16 Cr (-1.8% YoY) for Q4 FY26.